Requires prescription drug containers be labeled with a description of the size, shape, color and imprint of the prescription drug it contains if such drug is in tablet or capsule form.
Summary
A02640 would amend New York’s Education Law to require prescription drug containers to include a physical description of the medication inside when the drug is dispensed in tablet or capsule form. The required description would cover the pill’s size, shape, color, and imprint, in addition to the existing label information such as the pharmacy name, prescription number, prescriber, patient name and address, and directions for use.
The bill is aimed at improving patient safety and medication identification. By adding a visual description of the pill to the prescription label, the measure is intended to help patients, caregivers, and pharmacists distinguish medications more easily, reduce confusion between similar-looking drugs, and potentially prevent dispensing or administration errors. The bill would take effect 90 days after becoming law.
Impact
The bill would amend subdivision 1 of section 6810 of the Education Law, expanding the mandatory labeling requirements for prescription drug containers in New York. Pharmacies would need to update labeling practices and potentially their software or workflow to ensure that tablet and capsule prescriptions include the added physical description information. The requirement would apply to prescription drugs generally, while controlled substances would remain subject to additional rules under the Public Health Law.
Sentiment
The available materials do not include committee debate or recorded votes, so there is no documented public sentiment from the legislative process in the provided record. Based on the bill’s text and caption, the measure appears to be framed as a patient-safety and medication-identification proposal rather than a controversial policy change.
Contention
No specific points of contention are reflected in the provided transcripts or voting history because none are available. Potential areas of concern, if discussed later, could include the administrative burden on pharmacies, label space limitations, and whether the added information would meaningfully improve safety for all patients versus only certain types of prescriptions.
Same As
Requires prescription drug containers be labeled with a description of the size, shape, color and imprint of the prescription drug it contains.
An act to amend Section 4073.5 of the Business and Professions Code, to amend Section 1367.22 of the Health and Safety Code, and to add Section 10123.190 to the Insurance Code, relating to prescription drugs.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.